- Home
- LRMR vs ENLV Comparison
LRMR vs ENLV Comparison
Compare LRMR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | ENLV |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 258.7M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LRMR | ENLV |
|---|---|---|
| Price | $4.87 | $0.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $16.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.7M | 756.6K |
| Earning Date | 04-29-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $0.66 |
| 52 Week High | $6.42 | $2.10 |
Technical Indicators
Market Signals| Indicator | LRMR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 37.33 |
| Support Level | $3.14 | $0.81 |
| Resistance Level | $5.37 | $1.19 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 59.21 | 13.06 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.